{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:33:23Z","timestamp":1783103603104,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euf.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T20:25:11Z","timestamp":1719433511000},"page":"1043-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-2169","authenticated-orcid":false,"given":"Daniele","family":"Robesti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazario","family":"Pio Tenace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Leni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Cannoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.06.007_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-020-02808-6","article-title":"pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging","volume":"477","author":"Raspollini","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.euf.2024.06.007_b0015","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials","volume":"164","author":"Van Der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/01.ju.0000055471.78783.ae","article-title":"Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder","volume":"169","author":"Bol","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410x.2000.00356.x","article-title":"Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer","volume":"85","author":"Tosoni","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.06.007_b0030","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. 4th ed., Vol. 8. International Agency for Research on Cancer; 2016."},{"key":"10.1016\/j.euf.2024.06.007_b0035","series-title":"TNM classification of malignant tumours","year":"2016"},{"key":"10.1016\/j.euf.2024.06.007_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1066896917730903","article-title":"Del Carmen Rodriquez Pena M, Rais-Bahrami S. Second opinion expert pathology review in bladder cancer: implications for patient care","volume":"26","author":"Gordetsky","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0045","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/1097-0142(20010401)91:7<1284::AID-CNCR1130>3.0.CO;2-E","article-title":"Impact of second opinion pathology in the definitive management of patients with bladder carcinoma","volume":"91","author":"Coblentz","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2024.06.007_b0050","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2009.11.049","article-title":"The role of pathology review of transurethral bladder tumor resection specimens in the modern era","volume":"183","author":"Lee","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13000-016-0466-6","article-title":"Usefulness of pT1 substaging in papillary urothelial bladder carcinoma","volume":"11","author":"Patriarca","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R","article-title":"The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder","volume":"66","author":"Younes","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2024.06.007_b0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2012.04.020","article-title":"Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion","volume":"44","author":"Brimo","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.anndiagpath.2006.12.014","article-title":"Muscularis mucosae of the urinary bladder revisited with emphasis on its hyperplastic patterns: a study of a large series of cystectomy specimens","volume":"11","author":"Vakar-Lopez","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0080","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/PAS.0b013e3181da7650","article-title":"Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens","volume":"34","author":"Paner","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0085","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/PAS.0b013e3181ce5066","article-title":"Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma","volume":"34","author":"Miyamoto","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euf.2024.06.007_b0090","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2021.39.15_suppl.4503","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16\u2013257","volume":"39","author":"Galsky","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.06.007_b0095","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.annonc.2020.08.848","article-title":"776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized\/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]","volume":"31","author":"Vaishampayan","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2024.06.007_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urolonc.2021.10.012","article-title":"Bladder-sparing combination treatments for muscle-invasive bladder cancer: a plea for standardized assessment and definition of clinical trials endpoints","volume":"40","author":"Basile","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.06.007_b0105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JCO.2022.40.6_suppl.435","article-title":"Study EV-103 cohort H: antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible","volume":"40","author":"Petrylak","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.06.007_b0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.06.007_b0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.euf.2024.06.007_b0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euo.2020.11.010","article-title":"Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS trial","volume":"4","author":"Szabados","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2024.06.007_b0125","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T20:26:42Z","timestamp":1747081602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2405456924000968"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.06.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}